Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications

References

• Avert. HIV and AIDS in East and Southern Africa regional overview. UNAIDS 2017. [cited 2019 Jul 20]. Available from: https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/overview
   Google Scholar
• Dwyer-Lindgren L, Cork MA, Sligar A, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570(7760):189–193.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Health Observatory (GHO) data - HIV/AIDS. 2018. [cited 2019 Jul 28]. Available from: http://www.who.int/gho/hiv/en/
   Google Scholar
• UNAIDS. Country factsheets NAMIBIA 2017 HIV and AIDS estimates. [cited 2019 Aug 02]. Available from: https://www.fast-trackcities.org/sites/default/files/UNAIDS%20Country%20Factsheets%20Namibia%202017.pdf
   Google Scholar
• Mataranyika PA, Kibuule D, Kalemeera F, et al. Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: findings and implications. Alexandria J Med. 2018;54:49–56.
   Web of Science ®Google Scholar
• Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5(1):18–26.
   PubMed Web of Science ®Google Scholar
• von Wyl V, Cambiano V, Jordan MR, et al. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PloS One. 2012;7(8):e42834.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822.
   PubMed Web of Science ®Google Scholar
• Kharsany ABM, Karim QA. HIV infection and AIDS in Sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10:34–48.
   PubMedGoogle Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - Recommendations for a public health approach - Second edition. 2016. [cited 2019 Aug 02]. Available from: https://www.who.int/hiv/pub/arv/arv-2016/en/
   Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Nishijima T, Kawasaki Y, et al. Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naive Asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 2017;31(3):105–112.
   PubMed Web of Science ®Google Scholar
• Kalemeera F, Mbango C, Mubita M, et al. Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia. Expert Rev Anti Infect Ther. 2016;14(8):777–783.
   PubMed Web of Science ®Google Scholar
• Mizushima D, Tanuma J, Kanaya F, et al. WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients. PloS One. 2013;8(11):e79885.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329–336.
   PubMed Web of Science ®Google Scholar
• Kalemeera FCM, Mubita M, Kibuule D, et al. The potential effect of using the Cockcroft-Gault method on tenofovir-associated renal impairment reports and on clinical decisions regarding tenofovir use in individual patients: implications for the future. Jn Infect Dis Preve Med. 2017;5(3).
   Google Scholar
• Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19(1):817.
   PubMedGoogle Scholar
• Koh HM, Suresh K. Tenofovir-induced nephrotoxicity: A retrospective cohort study. Med J Malaysia. 2016;71(6):308–312.
   PubMedGoogle Scholar
• Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58(10):1473–1480.
   PubMed Web of Science ®Google Scholar
• Quesada PR, Esteban LL, Garcia JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–872.
   PubMed Web of Science ®Google Scholar
• Nartey ET, Tetteh RA, Yankey BA, et al. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana. BMC Res Notes. 2019;12(1):445.
   PubMedGoogle Scholar
• Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004–2012. PloS One. 2013;8(6):e66223.
   PubMed Web of Science ®Google Scholar
• Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029–1040.
   PubMed Web of Science ®Google Scholar
• Gilead. Highlights of prescribing information Truvada. [cited 2019 Jul 28]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
   Google Scholar
• Salome T, Kasamba I, Mayanja BN, et al. The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis. AIDS Res Ther. 2016;13(1):28.
   PubMedGoogle Scholar
• Huang YS, Chan CK, Tsai MS, et al. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients. J Microbiol Immunol Infect. 2017;50(5):595–603.
   PubMedGoogle Scholar
• Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PloS One. 2011;6(7):e22661.
   PubMed Web of Science ®Google Scholar
• Republic of Namibia. Ministry of health and social services (MoHSS). National Guidelines for Antiretroviral Therapy. 2016. [cited 2019 Aug 02]. Available from: https://aidsfree.usaid.gov/sites/default/files/na_national_guidelines_art.pdf
   Google Scholar
• Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25(13):1603–1609.
   PubMed Web of Science ®Google Scholar
• Choi AI, Rodriguez RA, Bacchetti P, et al. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007;72(11):1380–1387.
   PubMed Web of Science ®Google Scholar
• Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–1009.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC. The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17(1):59–71.
   PubMed Web of Science ®Google Scholar
• Diana NE, Naicker S. Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis. 2016;9:223–234.
   PubMed Web of Science ®Google Scholar
• Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42(10):1488–1495.
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Klotman PE, D’Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28(6):513–522.
   PubMed Web of Science ®Google Scholar
• Kalim S, Szczech LA, Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol. 2008;28(6):556–562.
   PubMed Web of Science ®Google Scholar
• Naicker S. End-stage renal disease in Sub-Saharan Africa. Kidney Int Suppl. 2013;3(2):161–163.
   Web of Science ®Google Scholar
• Moosa MR, Van der Walt I, Naicker S, et al. Important causes of chronic kidney disease in South Africa. S Afr Med J. 2015;105(4):2681.
   PubMed Web of Science ®Google Scholar
• Rwegerera GM, Molefe-Baikai OJ, Masaka A, et al. Prevalence of chronic kidney disease using estimated glomerular filtration rate among diabetes patients attending a tertiary clinic in Botswana. Hosp Pract (1995). 2018;46(4):214–220.
   PubMedGoogle Scholar
• Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. J Renal Injury Prev. 2014;3(4):109–110.
   PubMedGoogle Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
   PubMedGoogle Scholar
• Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. Clin J Am Soc Nephrol. 2009;4(11):1811–1817.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Komatsu H, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PloS One. 2012;7(1):e29977.
   PubMed Web of Science ®Google Scholar
• Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dialysis Trans. 2006;21(10):2809–2813.
   PubMed Web of Science ®Google Scholar
• Peters PJ, Moore DM, Mermin J, et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int. 2008;74(7):925–929.
   PubMed Web of Science ®Google Scholar
• Kalemeera F, Oberholster C, Segamwenge I, et al. Renal function outcomes in patients receiving TDF-containing antiretroviral therapy: A retrospective pilot study in Namibia. IJPSR. 2018;9(10):4273–4279.
   Google Scholar
• Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–307.
   PubMed Web of Science ®Google Scholar
• Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India. Indian J Sex Transm Dis. 2010;31(1):30–34.
   PubMedGoogle Scholar
• Nishijima T, Kawasaki Y, Mutoh Y, et al. Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo. Sci Rep. 2017;7(1):14565.
   PubMedGoogle Scholar
• Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46(8):1271–1281.
   PubMed Web of Science ®Google Scholar
• Karim R, Mack WJ, Kono N, et al. Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women’s interagency HIV study (WIHS). J Clin Endocrinol Metab. 2013;98(4):E610–E618.
   PubMed Web of Science ®Google Scholar